Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
Protocol # 22-383

Status

Recruiting

Description

This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.

Condition

  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides
  • Adoptive Cellular Immunotherapy
  • Cell Therapy

Interventions

  • MT-101
  • MT-101 + Conditioning (Lymphodepleting) Chemotherapy

Phase

Phase 1/Phase 2

Study Type

Interventional

Further Study Details

Primary Outcome:

  • Safety and Tolerability of MT-101

Secondary Outcome:

  • MT-101 cell kinetics in blood
  • The objective response rate

Enrollment

40

Study Start Date

December 15, 2021

Eligibility

  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No

Sponsors

Myeloid Therapeutics

Source

Myeloid Therapeutics

Official title

A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma

Clinicaltrials.gov Identifier

NCT05138458

     

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.